No. events | Unadjusted | Adjusted for age, metastatic disease, histology and local treatment | |||
---|---|---|---|---|---|
Hazard ratio 95% CI | p value | Hazard ratio 95% CI | p value | ||
Central axis | |||||
All (n = 320) | |||||
EFS | 177 | 1.48 (1.08–2.03) | 0.02 | 1.27 (0.89–1.82) | 0.19 |
OS | 154 | 1.47 (1.05–2.06) | 0.03 | 1.20 (0.82–1.75) | 0.36 |
Localised (n = 220) | |||||
EFS | 102 | 1.47 (0.97–2.24) | 0.07 | 1.33 (0.82–2.16) | 0.24 |
OS | 87 | 1.46 (0.93–2.30) | 0.10 | 1.15 (0.69–1.92) | 0.58 |
Extremity | |||||
All (n = 312) | |||||
EFS | 140 | 1.56 (1.12–2.18) | 0.009 | 1.75 (1.18–2.60) | 0.005 |
OS | 112 | 1.69 (1.17–2.45) | 0.006 | 1.59 (1.02–2.46) | 0.04 |
Localised (n = 253) | |||||
EFS | 99 | 1.68 (1.13–2.50) | 0.01 | 1.56 (1.00–2.43) | 0.05 |
OS | 75 | 1.86 (1.18–2.93) | 0.007 | 1.68 (1.00–2.81) | 0.05 |
Pelvic disease | |||||
All (n = 168) | |||||
EFS | 100 | 1.36 (0.90–2.05) | 0.14 | 1.05 (0.65–1.70) | 0.84 |
OS | 90 | 1.32 (0.85–2.04) | 0.21 | 0.98 (0.60–1.62) | 0.94 |
Localised (n = 107) | |||||
EFS | 56 | 1.22 (0.69–2.15) | 0.51 | 0.98 (0.51–1.89) | 0.96 |
OS | 51 | 1.17 (0.64–2.14) | 0.61 | 1.01 (0.51–2.03) | 0.97 |